FOSUN PHARMA announced that its holding subsidiary HENLIUS and its holding subsidiary have recently received approval from the National Medical Products Administration to conduct clinical trials for the use of injectable HLX43 combined with Sruvulimab injection to treat patients with advanced/metastatic solid tumors. HENLIUS plans to initiate the phase Ib/II clinical trial for this treatment plan in China once the conditions are met.
复星医药：控股子公司获药品临床试验批准
Fosun Pharma: Controlled subsidiary obtains approval for pharmaceutical clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated